Pharvaris said it reported positive topline results from its pivotal CHAPTER-3 Phase 3 study of deucrictibant XR to prevent hereditary angioedema attacks.
- The trial met its main goal, showing a clear reduction in attack frequency versus placebo across all hereditary angioedema types studied.
- Safety looked consistent with prior data, supporting a potential oral alternative to injectable prevention options.
- Additional efficacy and safety details will be presented at upcoming medical congresses.
- Regulatory submissions for the preventive use are planned to start in the first half of 2027.
PHVS•
